We are live on ! Find out more

1,737 hedge funds and large institutions have $138B invested in Pfizer in 2013 Q4 according to their latest regulatory filings, with 210 funds opening new positions, 590 increasing their positions, 754 reducing their positions, and 62 closing their positions.

New
Increased
Maintained
Reduced
Closed

239% more first-time investments, than exits

New positions opened: 210 | Existing positions closed: 62

8% more funds holding

Funds holding: 1,6061,737 (+131)

4% more capital invested

Capital invested by funds: $133B → $138B (+$4.97B)

4% more call options, than puts

Call options by funds: $1.28B | Put options by funds: $1.23B

0.48% less ownership

Funds ownership: 73.66%73.18% (-0.48%)

2% less funds holding in top 10

Funds holding in top 10: 254250 (-4)

22% less repeat investments, than reductions

Existing positions increased: 590 | Existing positions reduced: 754

Holders
1,737
Holders Change
+131
Holders Change %
+8.16%
% of All Funds
50.39%
Holding in Top 10
250
Holding in Top 10 Change
-4
Holding in Top 10 Change %
-1.57%
% of All Funds
7.25%
New
210
Increased
590
Reduced
754
Closed
62
Calls
$1.28B
Puts
$1.23B
Net Calls
+$44.3M
Net Calls Change
-$16M
Name Holding Trade Value Shares
Change
Change in
Stake
WCMNY
226
Westchester Capital Management (New York)
New York
$63M -$25.6M -879,861 -29%
MSA
227
Mason Street Advisors
Wisconsin
$62.8M +$7.78M +267,488 +14%
T
228
Thomaspartners
Massachusetts
$62.2M +$12.4M +424,697 +25%
FRM
229
Foundation Resource Management
Arkansas
$61.7M -$269K -9,227 -0.4%
RJA
230
Raymond James & Associates
Florida
$61.5M -$6.34M -217,689 -9%
AAMU
231
AEGON Asset Management (UK)
United Kingdom
$61.1M +$10.2M +351,827 +20%
JMPWA
232
JP Morgan Private Wealth Advisors
California
$60.8M +$3.45M +118,518 +6%
PIA
233
Piedmont Investment Advisors
North Carolina
$60.5M -$11.5M -396,699 -16%
FI
234
Focused Investors
California
$60M -$669K -22,977 -1%
WCM
235
Winton Capital Management
United Kingdom
$59.7M +$8.13M +279,382 +16%
MHC
236
Meyer Handelman Company
New York
$59.1M -$1.79M -61,343 -3%
Calamos Advisors
237
Calamos Advisors
Illinois
$59M -$6.17M -211,860 -9%
GH
238
GAM Holding
Switzerland
$58.4M -$4.05M -139,246 -6%
PC
239
Polar Capital
United Kingdom
$58.4M +$4M +137,416 +7%
Millennium Management
240
Millennium Management
New York
$58.4M +$47.7M +1,637,574 +441%
KBG
241
Kahn Brothers Group
New York
$58.2M -$18.7M -641,088 -24%
RCAMU
242
Rothschild & Co Asset Management US
Connecticut
$58.1M -$11M -377,767 -16%
MHI
243
Miller Howard Investments
New York
$57.4M -$136K -4,690 -0.2%
HIMCH
244
Hartford Investment Management Co (HIMCO)
Connecticut
$57.1M -$4.81M -165,225 -8%
FAF
245
Fjarde Ap-fonden
Sweden
$56.8M -$2.57M -88,253 -4%
CM
246
Castleark Management
Illinois
$56.7M +$56.6M +1,945,177 +28,393%
GIBU
247
Gulf International Bank (UK)
United Kingdom
$56.2M +$56.3M +1,934,862 New
AG
248
Aperio Group
California
$56M -$49.5M -1,700,213 Closed
FQ
249
First Quadrant
California
$55.6M +$1.66M +57,022 +3%
DKCM
250
Davidson Kempner Capital Management
New York
$55M

PFE Hedge Fund Activity: Q4 2013 in Review

1,737 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Pfizer (PFE) for Q4 2013, worth a combined $138B — up 3.7% from $133B a quarter earlier.

Buyers outnumbered sellers: 210 funds opened new PFE positions and 62 closed out — a net gain of 148 holders — while 590 added to existing stakes and 754 trimmed.

The largest buyer was Renaissance Technologies, opening a new position worth an estimated $230M. The largest seller was Grantham, Mayo, Van Otterloo & Co (GMO), cutting an estimated $642M.

  • 1,737 institutional investors held Pfizer (PFE) as of Q4 2013, up from 1,606 in Q3 2013.
  • Funds reported $138B of Pfizer stock for Q4 2013, up 3.7% quarter-over-quarter.
  • 210 funds opened new Pfizer positions in Q4 2013 and 62 closed out, a net change of +148 holders.
  • The largest Pfizer buyer in Q4 2013 was Renaissance Technologies, an estimated $230M added.
  • The largest Pfizer seller in Q4 2013 was Grantham, Mayo, Van Otterloo & Co (GMO), an estimated $642M sold.

Based on aggregated 13F filings for Q4 2013.